Olanzapine is a second-generation (atypical) antipsychotic medication. FDA has recently approved olanzapine in combination with samidorphan to attenuate olanzapine-induced weight gain.

**FDA-approved Indications**

- Schizophrenia if the patient is over the age of 13 years

- Bipolar I disorder, for acute treatment of manic or mixed episodes.

- Olanzapine also has approval for use with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), in patients with episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression. It is essential to recognize that olanzapine is not FDA-approved for patients under the age of thirteen years. The combination of olanzapine with fluoxetine does not have approval for patients under the age of 10 years.

- The FDA has recently approved olanzapine in combination with samidorphan to attenuate olanzapine-induced weight gain for schizophrenia and bipolar I disorder.

**Off-label Clinical Uses**

- Acute agitation

- Delirium

- Anorexia nervosa

- Chemotherapy-induced nausea and vomiting (CINV)